Tech Center 1600 • Art Units: 1636 1637 1653
This examiner grants 48% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18640031 | METHODS AND COMPOSITIONS FOR INHIBITING OXIDATIVE STRESS | Final Rejection | President and Fellows of Harvard College |
| 16976047 | EVOLVED CAS9 VARIANTS AND USES THEREOF | Final Rejection | President and Fellows of Harvard College |
| 17924304 | SAFE POTENT SINGLE VECTOR PLATFORM VACCINE AGAINST COVID-19 | Non-Final OA | The Regents of the University of California |
| 17778254 | SPLIT-ENZYME SYSTEM TO DETECT SPECIFIC DNA IN LIVING CELLS | Final Rejection | The Regents of the University of California |
| 16321777 | EXPRESSION OF PTEN-LONG WITH ONCOLYTIC VIRUSES | Non-Final OA | OHIO STATE INNOVATION FOUNDATION |
| 17816061 | Engineered Alum-binding SARS-CoV-2 Immunogens | Final Rejection | Massachusetts Institute of Technology |
| 17929013 | METHODS FOR RAPID CLONING AND EXPRESSION OF HLA CLASS I CELLS | Non-Final OA | Board of Regents, The University of Texas System |
| 19050083 | METHOD FOR DETECTING THE BIOLOGICAL ACTIVITY OF RECOMBINANT HUMAN GROWTH HORMONE MEDICINE | Final Rejection | National Institutes for Food and Drug Control |
| 17617731 | MEMBRANE ATTACK COMPLEXES AND USES THEREOF | Final Rejection | The Brigham and Women's Hospital, Inc. |
| 18088317 | OPTIMIZED GENE EDITING UTILIZING A RECOMBINANT ENDONUCLEASE SYSTEM | Non-Final OA | UNIVERSITY OF SOUTHERN CALIFORNIA |
| 17778211 | TETANUS TOXOID AND CRM-BASED PEPTIDES AND METHODS OF USE | Final Rejection | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. |
| 18659841 | COMPOSITIONS AND METHODS FOR HIV QUASI-SPECIES EXCISION FROM HIV-1-INFECTED PATIENTS | Non-Final OA | Drexel University |
| 18009731 | A CELLULAR MARKER OF COVID SEVERITY | Non-Final OA | Sorbonne Universite |
| 18007287 | METHODS TO STIMULATE IMMUNE RESPONSES TO MUTANT RAS USING NUCLEATED CELLS | Non-Final OA | STEMCELL TECHNOLOGIES CANADA INC. |
| 18035240 | MODIFIED NK CELLS WITH REDUCED CCR5 EXPRESSION AND METHODS OF THEIR USE | Non-Final OA | The United States of America, as represented by the Secretary, Dept. of Health and Human Services |
| 17291199 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING AMYOTROPHIC LATERAL SCLEROSIS | Non-Final OA | Ionis Pharmaceuticals, Inc. |
| 17933369 | UNIVERSAL DONOR CELLS | Non-Final OA | CRISPR THERAPEUTICS AG |
| 17923018 | Feline Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine | Non-Final OA | Intervet Inc. |
| 18525193 | METHOD FOR IDENTIFYING INTERVENTIONS THAT CONTROL THE TRANSLATIONAL ACTIVITY OF RIBOSOMAL PROTEINS IN DIFFERENTIAL MRNA EXPRESSION | Non-Final OA | BREITENBACH-KOLLER, HANNELORE |
| 18520555 | LINEAGE REPORTER SYNTHETIC CHROMOSOMES AND METHODS OF USE | Final Rejection | CarryGenes Bioengineering, LLC |
| 17813568 | CELL-FREE PROTEIN EXPRESSION USING ROLLING CIRCLE AMPLIFICATION PRODUCT | Non-Final OA | Global Life Sciences Solutions Operations UK Ltd |
| 18366237 | PLATELET TARGETED TREATMENT | Non-Final OA | PLATELET TARGETED THERAPEUTICS, LLC |
| 17429801 | COMPOSITION COMPRISING A MIXTURE OF DNA MOLECULES, USES THEREOF AS BIOLOGICAL INHIBITOR AND METHOD FOR PRODUCTION | Final Rejection | KOPPERT B.V. |
| 18246270 | BIFUNCTIONAL LENTIVIRAL VECTORS ALLOWING THE BS-GLOBIN SILENCING AND EXPRESSION OF AN ANTI-SICKLING HBB AND USES THEREOF FOR GENE THERAPY OF SICKLE CELL DISEASE | Non-Final OA | UNIVERSITÉ DE PARIS |
| 17744457 | METHODS FOR INCREASING THE RATE OF GENETIC PROGRESS AND GENERATING INBRED LINES IN NON-HUMAN MAMMALS | Final Rejection | Inguran, LLC |
| 16195552 | METHODS FOR INCREASING THE RATE OF GENETIC PROGRESS AND GENERATING INBRED LINES IN NON-HUMAN MAMMALS USING GAMETES DERIVED FROM EMBRYOS | Final Rejection | Inguran, LLC |
| 17796284 | METHODS OF DIAGNOSING AND CLASSIFYING VIRAL INFECTIONS | Final Rejection | MeMed Diagnostics Ltd. |
| 17905315 | Reagents and methods for preventing, treating or limiting severe acute respiratory syndrome (SARS) coronavirus infection | Final Rejection | PHYLEX BIOSCIENCES, INC. |
| 18005813 | T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof | Non-Final OA | Cue Biopharma, Inc. |
| 18018759 | COMPOSITIONS AND METHODS FOR IMPROVED VACCINATION | Non-Final OA | Combined Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy